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Background: The immune non-recognition is often the underlying cause of failure in tumor immunotherapeutic.
This is because most tumor-related antigens are poorly immunogenic, and fail to arouse an efficient immune
response against cancers. Here we synthesized a novel TLR7 agonist, and developed a safe and effective
immunotherapeutic vaccine by conjugating this TLR7 agonist with the pluripotency antigen OCT4.
Methods: Purified recombinant OCT4 protein was covalently linked with a novel TLR7 agonist to form a TLR7-OCT4
conjugate (T7-OCT4). After conjugation, the in vitro release of IL-12 and IFN-γ was observed in spleen lymphocytes.
Mice were immunized with TLR7-OCT4, and the release of IFN-γ, the percentages of CD3+/CD8+ T cells and the
OCT4-specific cytotoxicity rates were measured. The immunized mice were challenged with mouse embryonic
carcinoma (EC), and the tumor volume and tumor weight were determined. Blood routine examination was performed
to evaluate the biosafety of TLR7 agonist and TLR7-OCT4 conjugate in mice.
Results: T7-OCT4 conjugate significantly increased the in vitro release of IL-12 and IFN-γ by mouse spleen lymphocytes.
In addition, the release of IFN-γ, the percentages of CD3+/CD8+ T cells and the tumor-specific cytotoxicity rates
in immunized mice were significantly higher. Importantly, in EC xenografted mice, immunization with T7-OCT4
conjugate decreased the growth of the tumor dramatically up to 90 %, as compared to mice immunized with
OCT4 protein or TLR7 agonist alone. Furthermore, blood routine examination demonstrated that no abnormalities
of the blood cells and components in the blood fluids were detected by T7-OCT4 and TLR7 agonist injections.
Conclusions: Our results showed that conjugating OCT4 protein to the novel TLR7 agonist produced a vaccine
which is effective and safe in preventing tumor growth in mice. Our results suggest that this type of vaccine
formulation has great potentiality in preventive vaccines against OCT4 expressing tumors.
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OCT4 (Octamer-binding transcription factor 4), also
known as POU5F1, is a member of the mammalian
POU family of transcriptional factors. It functions as a
key regulator of the self-renewal and pluripotency of
embryonic stem (ES) cells [1]. OCT4 has been reported
to be highly expressed in many tumors, such as carcin-
omas of breast [2], testis, bladder [3], germ-cell tumors,
and in cancer stem cells [4]. Tumors with intense OCT4
expression have been associated with further disease
progression, greater degree of metastasis, and shorter
cancer related survival [5, 6]. Kavita et al. have shown
that OCT4-specific T cells could be readily detected in
freshly isolated T cells from over 80 % of healthy donors,
as compared to 35 % of patients with newly diagnosed
germ-cell tumors [7], suggesting that diminishing im-
mune response to OCT4 may lead to the generation and
development of germ-cell tumors. OCT4 is highly
expressed in tumor cells, but is either absent or at very
low level in a variety of normal cells [8], indicating that
it is a potential tumor stem cell biomarker and an ideal
target in cancer therapy [9].
Testis embryonic carcinoma (EC), a highly malignant
germ-cell tumor, occurs primarily in young adults. EC
cells, the malignant stem cells of teratoma, exhibit a
striking over-expression of the stem-related protein
OCT4 [4]. Thus, we hypothesized that OCT4 would be
a very powerful inducer of immune response to EC tu-
mors. As most protein, peptide and DNA antigens are
poorly immunogenic and often fail to arouse an efficient
immune response against cancers, it is important to find
a strategy to enhance the immunogenicity of OCT4.
Many studies have demonstrated that conjugation of
Toll-like receptors (TLRs) ligands and antigens offer
great advantages over non-coupled antigens [10]. TLRs
are a family of proteins expressed in many types of cells
including immune cells (DCs, macrophages, B cells, T
cells et al.) and other tissue cells. TLR-4, TLR-5, and the
heterodimers TLR-1/TLR-2 and TLR-2/TLR-6 are lo-
cated on the cell surface. Conversely, TLR-3, TLR-7,
TLR-8, and TLR-9 are located within endosomal com-
partments of the cell. TLRs are activated by appropriated
ligands and the Toll-like receptor (TLR) signaling path-
ways play critical roles in many host immune defenses.
TLRs recognize specific pattern molecules found in
many microbial pathogens called pathogen-associated
molecular patterns (PAMPs) and initiate signaling cas-
cades to arouse immune responses which result in the
eradication of invading pathogens. Thus, agonists of
TLRs have aroused broad interest for the immunother-
apy of cancer, because most of tumor cells express high
levels of tumor-specific antigens [11, 12].
To date, at least 10 members of Toll-like receptors
(TLRs) have been identified in human with differentTLRs having different respective ligands. Of all TLRs,
only TLR7/8 recognizes GU-rich short single-stranded
RNA (ssRNA) as well as small synthetic molecules such
as nucleoside analogues and imidazoquinolines. This
creates the opportunity of screening and modifying
highly efficient TLR7 agonists for the enhancing of im-
mune response. Furthermore, TLR7/8 agonists not only
activate the antigen-presenting cells (APCs), but also
promote the activation of T cells and natural killer (NK)
cells [13, 14]. Activation of TLR-7 leads to the engage-
ment of MyD88, MAL, IRAKs, and IKKα, which pro-
mote IRF activation and the production of Type 1 IFNs
and pro-inflammatory cytokines [15, 16]. In addition,
synthetic imidazoquinoline-like molecules such as resi-
quimod (R-848) and imiquimod (R-837) have also been
shown to activate NF-κB through TLR7 [17, 18].
Here we showed that a conjugate of exogenous puri-
fied recombinant OCT4 protein covalently linked to a
TLR7 agonist (T7-OCT4) could elicit a surprisingly strong
anti-tumor effect on EC tumors by inducing tumor-
specific immune response. The mechanisms by which this
T7-OCT4 complex promotes immune responses were
investigated.
Materials and methods
Bacterial strains, plasmids, cell lines and mice
Escherichia coli (E.coli) strain BL21 and PGEX-KG-
mouse-OCT4 were maintained in our lab. E. coli was
regularly grown in Luria Broth (LB) media at 37 °C with
shaking at 200 rpm or on media (supplemented with
100 μg/ml ampicillin LBAmp) solidified with 1.5 % agar.
LLC Lewis lung cancer cells or mouse embryonic carcin-
oma F9 cells were maintained in our lab and cultured in
Dulbecco's Modified Eagle's Medium (DMEM, Hyclone),
supplemented with 10 % fetal bovine serum (FBS,
Hyclone), 100 μg/mL penicillin (Ameresco) and 100 μg/
mL streptomycin (Ameresco). Cells were cultured at 37 °C
in a humidified atmosphere with 5 % CO2. BALB/c mice
at 6 weeks of age were purchased from the Medical
Laboratory Animal Centre of Guangdong Province, China.
The experiments were carried out in accordance with rec-
ommendations cited in the Guide for the Care and Use of
SPF (Special Pathogens free) Animal Center of Shenzhen
University, Guangdong Province, China.
Synthesis of TLR7 agonist
The TLR7 agonist was synthesized in our laboratory,
compound 5 was synthesized from 2,6-dichloropurine
according to the published method [19, 20], The TLR7
agonist (compound 6) was separated from the hydrolysis
of compound 5 in concentrated HCl (Fig. 1) as a free
acid. Briefly, 100 mg of compound 5 was dissolved in
10 mL of concentrated HCl; the mixture was stirred at
room temperature for 12 h, heated at 40 °C for 4 h;
Fig. 1 Schematic illustration on the synthesis of TLR7 agonist (T7)
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to remove the solvent. Then, the residue was dissolved in
10 mL of 5 % Na2CO3 in water, stirred for 30 min, and
filtered. The clear filtrate was acidified with 5 % HCl at
5-10 °C, the precipitated product was filtered and washed
three times with water, dried under vacuum at 60 °C, for
4 h to obtain the final product of TLR7 agonist (T7) as
white powder. The structure of T7 was determined by
Nuclear Magnetic Resonance assay (1H; 13C NMR).
Production and purification of recombinant OCT4
immunogen and its conjugation with T7
Recombinant mouse OCT4 was produced by transfec-
tion of plasmid PGEX-KG-mouse-OCT4 into Bacterial
strain BL21. The expressed protein was purified with
glutathione sepharose beads (GE healthcare) at 4 °C, and
assayed using a DC protein assay kit (BioRad). The benze-
necarboxylic acid group on TLR7 agonist enabled facile
coupling to protein with free amino using well established
conjugation chemistry. To prepare a conjugate that could
be administrated into mice and conveniently monitored
spectrophotometrically, we chose EDC and NHS to acti-
vate carboxylic acid as active ester. The TLR7 agonist,
EDC and NHS were mixed at 1:1:1 ratio in DMSO and in-
cubated in the dark at room temperature overnight. Then
the activated TLR7 agonist was added to OCT4 protein at
40-fold molar excess in PBS, and incubated at 4-8 °C over-
night. To remove excess TLR7 agonist and catalyst EDC/NHS,the reaction mixture was washed with PBS three
times on 10 000 MWCOMicrocon filtration device (Milli-
pore). The lyophilized conjugate was stable for at least
6 months at −20 °C.
Stimulation of mouse spleen lymphocytes in vitro
Mouse spleen lymphocytes were isolated from BALB/c
mice and grown in RPMI 1640 medium with 10 % FBS.
Cells were seeded into 96-well plates at a density of 4 × 105
cells per well. Different testing compounds were added to
the cell culture medium at a final concentration ranging
from 0.01 to 10 μM as indicated and incubated for 24 h.
The levels of IL-12 and IFN-γ in cell culture supernatants
were determined using enzyme-linked immunosorbent
assay (ELISA) (eBioscience), according to the manufac-
turer’s instructions.
Immunizations in mice
All experiments were routinely performed in groups of 8
mice each. On Day 1, 14, 28 and 42, mice were adminis-
trated (i.p.) PBS, OCT4 protein (15.6 μg in PBS per
mouse), TLR7 agonist (1.9 μg in PBS per mouse), or T7-
OCT4 conjugate (17.5 μg). Cells were harvested from
spleens on the 3rd day after the last vaccination, and 2.5 ×
105 single cell suspensions from individual mice were in-
cubated with 10 μg/ml OCT4 protein for 24 h. Then cul-
ture supernatants were collected and assayed for cytokine
inductions by ELISA.
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2.5 × 106 spleen lymphocytes from immunized mice (PBS,
TLR agonist, OCT4 and T7-OCT4) were seeded in 96-
well plates and stimulated with 10 μg/mL OCT4 antigen
or PBS alone every 24 h twice. Three days later, cells were
collected and washed with PBST (0.05 %Tween in PBS),
incubated with 5 % BSA for 1 h, stained with anti-CD4
FITC, anti-CD8 PE at 1 μg/ml final concentration on ice
overnight, and then washed with PBST 3 times and imme-
diately analyzed by flow-cytometry (Becton Dickinson).The CTL assays
Spleen from immunized mice were removed 3 days after
the last injection, and single lymphocyte cell suspensions
were obtained by teasing the organs through a sterile
nylon mesh. Effector Cells (1.25 × 105) were treated with
10 μg/mL OCT4 protein and again 24 h later. Cells were
maintained for 3 days in a humidified 5 % CO2 incuba-
tor at 37 °C in RPMI 1640 medium containing 5 % fetal
bovine serum in 96-well plates. Before the target cells
(LLC or F9 cells) were added, 100 μl of supernatants in
effector cells should have been removed.
Target cells were prepared by incubating LLC cells or
F9 cells in tissue culture for 12–16 h. Target cells were
diluted in RPMI 1640 with 5 % FBS and 10 mM HEPES
at the concentration of 1x105/ml and added 100 μl to ef-
fector cells in 96-well round-bottomed plates. After a
5 h incubation period at 37 °C, the levels of LDH in the
supernatants released by target cells were determined
according to the manufacturer’s instructions (Promega).Tumor prevention of T7-OCT4 vaccine in mice
All experiments were routinely performed in groups of 8
mice per group. Mice were immunized and challenged
with tumors according to the method reported by Vani
et al. [21]. Briefly, mice were administrated (i.p.) with
PBS, OCT4 protein (15.6 μg in PBS per mouse), TLR7
agonist (1.9 μg in PBS per mouse), TLR7+ OCT4 (mix-
ture of 15.6 μg OCT4 protein and 1.9 μg TLR7 agonist),
or T7-OCT4 conjugate (17.5 μg) on Day1, 14, 28 and
Day42. On Day35, mice were injected subcutaneously
with 100 μl of F9 cell suspension (2 × 106 cells) in the
mid-back region, and sacrificed 14 days post-injection of
F9 cells. Tumor xenografts were surgically dissected,
weighed, and measured. Tumor volume was calculated ac-
cording to the equation Length ×Width2/2 with the length
(mm) being the longer axis of the tumor. The generation
of microvessels in tumors was observed using transparent
dorsal skin fold window chamber (see Additional file 1).
The experiments were carried out in accordance with rec-
ommendations cited in the Guide for the Care and Use of
Laboratory Animals of Shenzhen University, Guangdong
Province, China.Blood routine examination
Blood samples are harvested from mice immunized with
PBS, OCT4 protein, TLR7 agonist, or T7-OCT4 conju-
gate on the 42th days. Blood was collected in anticoagu-
lant tubes from the orbital sinus by removing the eyeball
from the socket quickly. Blood routine examination was
performed using a routine blood test instrument (Mind-
ray RJ-0C107223) in the affiliated hospital of Shenzhen
university by an experienced clinical doctor.
Statistical analysis
All data were presented as mean ± SD. The results were
compared by an analysis of variance. All statistical calcu-
lations were performed with Excel software package. A
p-value < 0.05 was regarded as statistically significant
difference.
Results
Synthesis of TLR7 agonist
TLR7 agonist (T7) was synthesized in our laboratory in
six steps according to the scheme presented in Fig. 1.
Mp: 280–282 °C; MS (ESI): m/z 360.30(MH+); and the
1H, 13C NMR were consistent with the structure
assigned (see Additional file 2: Figure S1).
Conjugation of TLR7 agonist to recombinant OCT4
protein
TLR7 agonist (T7) could be easily coupled to proteins
and peptides antigens through the amide banding com-
monly used in peptide chemistry. In this study, we
coupled T7 to OCT4 protein directly by NHSA-EDC
procedure, yielded the conjugated antigen (T7-OCT4)
(Fig. 2a) which was identified and characterized by MS
spectrum (Fig. 2b). The ratio of T7 and OCT4 was de-
termined to be 4:1. The molecular weight of TLR7 agon-
ist was 359 Da, and the molecular weight of OCT4
protein before and after conjugation were 64.9 KDa and
66.4 KDa, respectively.
T7- OCT4 induced potent cytokine release in vitro in
spleen derived lymphocytes
Since the TLR7 agonist we used is not commercially
available, we first evaluate the immunological activity of
this TLR7 agonist and determine the optimal dose.
TLR7 agonist was conjugated to small peptides M2e or
MG7 (T7-M2e or T7-MG7). M2e peptide (sequence
MSLLTEVETPTRNEWECRCSDSSD) is the 24 amino-
acid extra-cellular domain of M2 protein (M2) which is
one of the most conserved antigens of influenza A virus.
MG7 peptide (KPHVHTK) is a mimic epitope recog-
nized by specific monoclonal antibody against gastric
cancer associated antigen MG7. Both M2e and MG7
peptides are poor-immunogenic, as they are short pep-
tides with low molecular weight. After incubation of
Fig. 2 Quantification of TLR7 agonist conjugated to OCT4. a: Schematic illustration on the conjugation of TLR7 agonist to protein. b: The molecular
weight of OCT4 before conjugation by mass spectrometry. c: The molecular weight of OCT4 after conjugation to T7 agonist by mass spectrometry.
The molecular ratio of TLR7 agonist: OCT4 is 4:1
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cytokine IL-12 and IFN-γ were determined by ELISA.
As shown in Fig. 3a-d, T7-M2e or T7-MG7, could
stimulate substantially higher levels of cytokines release,
as compared to TLR7 agonist alone (p < 0.001), indicat-
ing that the T7-M2e or T7-MG7 (0.1-1.0 μM) conjugates
could activate the immune response more efficiently. T7
agonist alone could stimulate lymphocytes cytokine re-
lease at concentrations over 1 μM (p < 0.001), but not
below 1 μM.
Next, we conjugated TLR7 agonist to the purified
OCT4 protein to produce T7-OCT4 conjugate and
measured its effect on the IL-12 and IFN-γ released by
the lymphocytes. The total amount of T7 in unconju-
gated and conjugated is equal. The molarity of OCT4 is
1/4 of T7 agonist since the ratio of conjugation bet-
ween TLR7 and OCT4 is 4:1. As shown in Fig. 3e and f,
the T7-OCT4 induced significantly higher levels of
IL-12 and IFN-γ release than that of control and T7 atindicated concentrations (0.1 μM, 0.5 μM, 1.0 μM)
(p < 0.0001). Moreover, T7-OCT4 induced obviously
higher levels of IL-12 than OCT4 and T7 +OCT4 at con-
centrations of 0.1 μM (p < 0.0001), 0.5 μM (p < 0.0001)
and 1.0 μM (p < 0.01). Similarly, T7-OCT4 induced re-
markably higher levels of IFN-γ than OCT4 and T7 +
OCT4 at concentrations of 0.1 μM (p < 0.0001) and
0.5 μM (p < 0.01). OCT4 and T7 +OCT4 did not cause
significant change in IL-12 at concentrations of 0.1 μM
and 0.5 μM, and did not cause significant change in IFN-
γ release at concentrations of 0.1 μM, however, OCT4 and
T7 +OCT4 at 1.0 μM caused a significant increase of IL-
12 (p < 0.01) and IFN- γ (p < 0.0001) release. This is pos-
sibly due to the non-specific immune response caused
by high concentration of OCT4 antigen. Taken to-
gether, these results suggested that T7-OCT4 at the
concentrations of 0.1-1.0 μM (the morality of T7 agon-
ist) could effectively stimulate lymphocytes immune
response.
Fig. 3 In vitro cytokine release in response to T7-OCT4 conjugates. Total murine spleen lymphocytes were isolated and treated with T7 agonist or T7
conjugates at various concentrations as indicated. Culture supernatants were harvested 24 h later, and cytokine levels were measured by immunoassay.
The results are a representative of at least two separate experiments in triplicate per treatment. (a and b) Levels of IL-12 and IFN-Ƴ released by spleen
lymphocytes treated with T7 agonist, M2e peptide and T7-M2e conjugate. (c and d) Levels of IL-12 and IFN-Ƴ released by spleen lymphocytes treated
with T7 agonist, MG7 peptide and T7-MG7conjugate. e and f: Levels of IL-12 and IFN-Ƴ released by spleen lymphocytes treated with PBS, T7 agonist,
OCT4 protein, T7 +OCT4 mixture and T7-OCT4 conjugate. Values are the means ± SD, n = 4; *, P < 0.01 vs Control;#, P < 0.01 vs OCT4; Δ,P < 0.01 vs T7 +OCT4.
(Note: The concentration in the Figure describes the molarity of T7 agonist. The molarity ratio of OCT4 protein: T7 agonist = 1:4)
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BALB/c mice xenografted with EC tumor
To observe the in vivo tumor-prevention effect of T7-
OCT4 vaccine, BALB/c mice were immunized with PBS,
T7, OCT4, T7 +OCT4 (mixture of T7 and OCT4), or
T7-OCT4 conjugate three times at biweekly intervals
(On Day1, 14, 28). After 35 days, mice were injected
subcutaneously with embryonic carcinoma F9 cells. On
day 42, one more immunization was given. Fourteen
days after post-injection of F9 cells, mice were sacrificed
and tumor xenografts were surgically dissected, weighed,
and measured. As shown in Fig. 4, immunization with
T7, OCT4, as well as T7 + OCT4 did not produce sig-
nificant growth inhibition as compared to that of control
(P > 0.05). However, tumor growth was significantly
inhibited by T7-OCT4 conjugate, the tumor volume and
weight were dramatically decreased (P < 0.001). Using
transparent dorsal skin fold window chamber, we found
that tumors in T7-OCT4 conjugate treated mice showed
decreased visible microvessels on Day 12 after tumor in-
jection (as showed in Additional file 3: Figure S2), ascompared to other treatment groups, which had abun-
dant microvessels in the tumor mass as early as Day 7
after tumor-injection.
T7-OCT4 vaccine induced tumor-specific immune
responses in vivo in BALB/c mice
We immunized mice with T7-OCT4 on Day 1, 14, 28
and 42. Three days after the last immunization, lympho-
cytes were isolated from spleen, incubated with OCT4
antigen for 24 h, then the lymphocytes release of IFN-γ,
the percentage of CD3+/CD8+ T cells, and the cytotox-
icity to tumor cells were determined. As shown in Fig. 5a,
the levels of IFN-γ in both T7-OCT4 and OCT4 groups
were significantly higher than that of control and T7
groups. Consistently, the percentages of CD3+/CD8+ T
cells are also remarkably higher (Fig. 5b). In addition,
the lymphocytes induced cytotoxicity rates of F9 cells
were highest in T7-OCT4 group, followed by T7 and
OCT4 groups as compared to the control. As for the
LLC Lewis lung cancer cells in which OCT4 antigen are
absent, only T7 treatment showed increased cytotoxicity
Fig. 4 T7-OCT4 conjugates inhibits xenograft tumor growth a:
Representative images of tumors derived from group Control, T7,
OCT4 and T7-OCT4. 2x106 F9 cells were injected subcutaneously
into the mid-back area of adult BALB/c mice. b: Tumors were
measured in three dimensions on day 14 post-injection of F9 cells.
Values are the means ± SD, n = 8; *, P < 0.001 vs Control. c: Weight
of xenograft tumors on day 14 post-injection of F9 cells. Values are
the means ± SD, n = 8; *, P < 0.001 vs Control
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pared to the control (Fig. 5c). These results indicated
that T7-OCT4 vaccine can induced OCT4-specific im-
mune responses, and the anti-tumor effect of T7-OCT4
are possibly centered on the activation of CD8 CTL that
recognize specific OCT4 tumor antigen.
Toxicity of T7 agonist and T7-OCT4 conjugate in mice
To evaluate the bio-safety of T7 agonist and T7-OCT4
conjugate in vivo, we performed the blood routine exam-
ination in animals administered with either PBS buffer,T7 agonist, OCT4 protein, or T7-OCT4 conjugate. The
most important physiological system the administered
compounds will interact is the blood fluids and their re-
spective components (e.g. blood cells and hemoglobin).
Therefore, it is crucial to determine the standard haema-
tology markers. As shown in Table 1, blood test results
showed no significant abnormalities in white blood cell
count, (WBC), red blood cell count (RBC), haemoglo-
bin (HGB), haematocrit (HCT), mean corpuscular vol-
ume (MCV), and platelet count (PLT). These results
suggest that T7 agonist or T7-OCT4 did not cause any
abnormalities of the blood cells and components in the
blood fluids.
Discussion
Research underlying the immune non-recognition in-
volved in the failure of tumor cells removal has led to
the widespread exploration of immunotherapeutic ap-
proach aiming at the development of immune-mediated
tumor destruction. To date, vaccines against pancreatic
cancer (telomerase peptides) [22], lung cancer (MUC1)
[23], breast cancer (HER2) [24], and prostate cancer
(prostatic acid phosphatase, PAP) [25] have been tested
clinically. In general, the clinical data clearly indicated
that these vaccines are effective therapeutics. In this
study, we used the pluripotency antigen OCT4 to acti-
vate the immune system against EC tumor cells and can-
cer stem cells, which are the root of tumor formation,
recurrence and metastasis.
Although vaccine targeting OCT4 antigen is expected
to achieve specific antitumor effect, especially on cancer
stem cells and germ tumor cells. However, most tumor
related antigens are poorly immunogenic, and often fail
to arouse an efficient immune response against cancers.
Consistently, our results also showed that although
OCT4 protein alone can promote the generation of IFN-
γ which are secreted by CD8+ T cells and CD4+ T cell-
s(especially TH1 cells)in vitro and in vivo, however,
immunization of OCT4 antigen alone in vivo could not
efficiently inhibit the growth EC tumors, suggesting that
although systemic immune response could be activated
by OCT4 protein, no tumor-specific immune responses
was observed in vivo during this process. It is possible
that systemic immune activation by free OCT4 antigen
does not create local cytokine and chemokine microen-
vironments required to mobilize immune cells to the site
of tumors, or that the free OCT4 antigen induced im-
mune cells could not effectively recognize the epitopes
of OCT4 antigen expressed in EC tumor cells.
Several studies have demonstrated that conjugation of
Toll-like receptors (TLRs) ligands and antigens pro-
duced better immunogenicity than non-coupled antigens
[10, 26]. For example, Wille et al. reported that
immunization with HIV-1 Gag protein conjugated to a
Fig. 5 T7-OCT4 vaccine induced tumor-specific immune responses. Mice were i.p. immunized with different vaccines on Day 1, 14, 28 and 42.
Three days after last immunization, a: Splenocytes were isolated and total splenocytes were re-stimulated with 10 μg/ml OCT4 antigen for 24 h,
and the production of IFN-γ in culture supernatants was measured using ELISA. b: Total splenocytes were labelled with PE-anti-mouse CD8 and
FITC-anti-mouse CD3, and the percentages of CD8+/CD3+ T cells in total splenocytes were measured using flow cytometry. c: Tumor-specific
in vitro CTL response was measured as described in methods. *, P < 0.01 vs group T7; #, P < 0.01 vs group OCT4. Bars shown are
mean ± SD (n = 5)
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antigen-specific Th1 and CD8+ T cell responses than un-
conjugated HIV-1 Gag protein [27, 28]. Jason et al. found
that immunization with the conjugate of whole OVA pro-
tein and TLR7 agonist resulted in around 1000-fold reduc-
tion in the frequency of bacteria in inoculated C57BL/6
mice, demonstrating a strikingly stronger ability to lower
bacterial burden and control the infection [29].
Similarly, we designed and synthesized a novel TLR7
agonist (T7). This TLR7 agonist is small-molecule TLR7
ligands. It can functionalize many low immunogenicity
antigens such as OCT4 to become potent immunosti-
mulants by simple standardized conjugation method.
The T7-OCT4 antigen serves as a model vaccine andTable 1 Blood test results for treated BALB/c mice
Group Control T7
WBC (109/L) 7.735 ± 1.520 6.318 ± 0.68
RBC (1012/L) 11.02 ± 0.307 11.114 ± 0.1
HGB (g/L) 157.142 ± 5.460 157.428 ± 5.
HCT (L/L) 0.486 ± 0.016 0.486 ± 0.01
MCV (10−12L) 44.142 ± 1.304 43.820 ± 1.4
PLT (109/L) 481.333 ± 42.250 401.000 ± 84
Abbreviations: white blood cell count, (WBC), red blood cell count (RBC), haemoglo
count (PLT)could be used as a single immunotherapy, or in combi-
nation with other therapies for cancer prevention and
treatment. Consistent to a previous study [26], our data
showed that conjugation of TLR7 agonist and OCT4
protein could lead to rapid induction of inflammatory
mediators IFN-γ and IL-12 in lymphocytes in vitro. The
in vivo data showed that the T7-OCT4 vaccine can in-
hibit tumor growth by arousing tumor-specific immune
responses. In summary, we synthesized a novel TLR7
agonist and conjugated with stemness antigen OCT4 to
develop a safe and effective immunotherapeutic tumor
vaccine. The vaccine is effectively against EC tumors and
also expected to be useful for immunotherapy of tumor
stem cells and other tumor cells which express OCT4OCT4 T7-OCT4
5 6.391 ± 0.987 8.510 ± 2.081
69 11.15 ± 0.309 11.12 ± 0.210
381 159 ± 5.099 158.428 ± 2.637
3 0.484 ± 0.017 0.480 ± 0.007
94 43.383 ± 0.286 43.185 ± 1.076
.052 452.285 ± 95.068 436.142 ± 51.181
bin (HGB), haematocrit (HCT), mean corpuscular volume (MCV) and platelet
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from growth, spread and metastasis. Potentially, this vac-
cine may be of great value for the prevention of tumor gen-
eration after the transplantation of stem cells or induced
pluripotent stem cells (iPS) into human body, as OCT4 is
indispensible for most stem cells to generate tumors.
Conclusions
Lack of immune recognition is the main cause of the tumor
cells escaping immune surveillance and resisting eradica-
tion by the immune system. To address this issue, many
cancer immunotherapy approaches are centered on the ac-
tivation of CD8 CTL that recognizes specific tumor anti-
gens. Here, we developed a novel TLR7 agonist and
conjugated OCT4 protein covalently linked to this agonist
(T7-OCT4). T7-OCT4 could elicit a surprisingly strong
anti-tumor effect on embryonic carcinoma (EC) by indu-
cing tumor-specific immune response in mice. Our results
demonstrated that vaccination of OCT4 antigen conjugated
to the novel TLR7 agonist is effective and safe against EC
tumors and other tumors which express OCT4 antigen.
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